Wakunaga Pharmaceutical Co., Ltd.
http://www.wakunaga.co.jp/english/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Wakunaga Pharmaceutical Co., Ltd.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.
Dainippon Sumitomo wins long-running licensing dispute with Wakunaga
Dainippon Sumitomo Pharma (DSP) has prevailed in a legal case brought against it by a smaller Japanese company regarding a terminated licensing deal for a quinolone antibacterial.
Wakunaga takes Japanese quinolone case to Supreme Court
Wakunaga Pharmaceutical has taken its fight with fellow Japanese company Dainippon Sumitomo Pharma (DSP) to the Supreme Court. The small firm has appealed a recent Osaka High Court decision that rejected its claims against DSP in a long-running dispute over a terminated 1998 licensing deal for a quinolone antibacterial. DSP brought the High Court appeal following a 2007 district court decision ordering it to pay ¥890 million ($8.9 million) in damages to Wakunaga (scripnews.com, March 27th, 2009). Wakunaga first filed suit in 2004, claiming then that Dainippon (which merged with Sumitomo Pharma in 2005) had acted improperly.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Other Names / Subsidiaries
-
- Wakunaga of America Co Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice